Civica to Invest $27.8 Million in New Testing Facility

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

Glenn Youngkin, governor of Virginia, announced on Sept. 8, 2022 that Civica, a non-profit generic drug company, will invest $27.8 million to establish a new laboratory testing facility at Meadowville Technology Park in Chesterfield County, VA.

The 55,000 ft2 facility will support Civica’s Petersburg pharmaceutical manufacturing operation through quality testing and development of new products. According to a press release, the project will create 51 jobs, as well as additional employment through the hosting of a scale-up manufacturing facility operated by Virginia Commonwealth University’s Medicines for All Institute.

“Civica’s investment is another transformational step forward in strengthening the advanced pharmaceutical manufacturing hub in the Richmond-Petersburg region and positioning Virginia as a key player in domestic drug manufacturing in America,” said Youngkin in the release. “Civica is a critical partner in the Commonwealth’s emerging pharmaceutical ecosystem that will ensure access to affordable, lifesaving medications while providing high-quality jobs and an incredible boost to our economy.”

“Civica’s new laboratory testing facility in Chesterfield County extends the footprint of the rapidly growing pharmaceutical manufacturing cluster in the region and will support the coalition’s long-term vision to serve as the world’s central access point for advanced pharmaceutical manufacturing and R&D,” said Caren Merrick, Viriginia Secretary of Commerce and Trade, in the release. “Today we celebrate Virginia’s vital role in addressing the shortage of affordable essential medicines in our nation and the investment in a new facility that will create high-paying jobs and accelerate research and innovation in the industry.”

Source: VEDP